Clinical Trials

Find a Trial

Trial Summary

Protocol No.EAY131-M/MATCH
StatusOPEN TO ACCRUAL
Principal InvestigatorMiller, Kathy
ScopeNational
PhasePhase II
Age GroupAdult
TitleMATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
DescriptionThis phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • 18 years or older
  • Measurable disease
For a full list of participation criteria, please visit clinicaltrials.gov.
Applicable Disease SitesAny Site
Participating InstitutionsIndiana University (IU)
  • Eskenazi Hospital
  • IU Health North (For use by Cancer Center CTO only)
  • IU Health West (For use by Cancer Center CTO only)
  • Indiana University Hospital / IU Simon Cancer Center
  • Spring Mill Medical Center
Treatment TypeTreatment
ContactCheri A West, RNPhone: 317-278-3021
Pager: 317-312-2375
Email: chawest@iupui.edu